NasdaqGS - Nasdaq Real Time Price USD

Vigil Neuroscience, Inc. (VIGL)

2.3200

-0.0500

(-2.11%)

At close: May 15 at 4:00:00 PM EDT

2.2900

-0.03

(-1.29%)

Pre-Market: 5:09:13 AM EDT

Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer’s disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter endi

GlobeNewswire 9 days ago

VIGL
-2.11%
Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease (AD) - WATERTOWN, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented data

GlobeNewswire last month

VIGL
-2.11%
Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know

Vigil Neuroscience (VIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks last month

VIGL
-2.11%
Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

– Announced positive data from Phase 1 clinical trial evaluating VG-3927 for potential treatment of Alzheimer’s Disease (AD); plans to initiate Phase 2 clinical trial in Q3 2025 – – On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – WATERTOWN, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neur

GlobeNewswire 2 months ago

VIGL
-2.11%
Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum

WATERTOWN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Stifel 2025 Virtual CNS Forum on Wednesday, March 19, 2025, at 9:00 a.m. ET. To register for the live webcast, please click here. The webcast will also be available on the Company’s website in the

GlobeNewswire 2 months ago

VIGL
-2.11%
Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 2 months ago

VIGL
-2.11%
Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Vigil Neuroscience, Inc. (NASDAQ:VIGL) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in the biotech space. There will always be […]

Insider Monkey 2 months ago

VIGL
-2.11%
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET. To register for the live webcast, please click here. The webcast will also be available on the Company’s web

GlobeNewswire 3 months ago

VIGL
-2.11%
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3

On Thursday, Vigil Neuroscience Inc. (NASDAQ:VIGL) released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer’s disease. Key takeaways from the Phase 1 clinical trial of VG-3927 include: Demonstrated a favorable safety and tolerability profile across all cohorts, including the elderly cohort. All related adverse events were mild or moderate in severity and self-resolving without drug discontinuations. No serious AEs were reported. Highly brain penetr

Benzinga 3 months ago

VIGL
-2.11%
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease (AD) - - Robust and dose-dependent reductions of sTREM2 were achieved demonstrating sustained functional target engagement – - Company plans to advance VG-3927 into a Phase 2 trial in the third quarter of 2025; Selects 25mg QD oral as a dose that fully engages desired pharmacology - WATERTOWN, Mass., Jan. 23, 2025 (GLOBE NEWSW

GlobeNewswire 3 months ago

VIGL
-2.11%
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

– On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 – – Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for 2Q 2025 – – Company well-positioned for continued operational progress in 2025 – WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment

GlobeNewswire 4 months ago

VIGL
-2.11%
Vigil Neuroscience to Present at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will be presenting at the following conferences in November: Stifel 2024 Healthcare ConferenceFormat: Fireside ChatDate/Time: Monday, November 18th at 4:45 p.m. ET Jefferies London Healthcare ConferenceFormat: Fireside ChatDate/Time: Wednes

GlobeNewswire 5 months ago

VIGL
-2.11%
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update

- Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of 2025 - - Data from Phase 1 clinical trial evaluating VG-3927 in Alzheimer’s Disease on track for first quarter of 2025 - WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the

GlobeNewswire 6 months ago

VIGL
-2.11%
Vigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stake

Key Insights Given the large stake in the stock by institutions, Vigil Neuroscience's stock price might be vulnerable...

Simply Wall St. 6 months ago

VIGL
-2.11%
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 11, 2024, at 10:30 a.m. ET. To register for the live webcast, please click here. The webcast will also be available on the Company’s website

GlobeNewswire 6 months ago

VIGL
-2.11%
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. 7 months ago

VIGL
-2.11%
FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial

This decision comes after the company submitted a complete response to the regulator.

Clinical Trials Arena 7 months ago

VIGL
-2.11%
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its ongoing Phase 1 clinical trial of VG-3927. The FDA’s decision was based on a complete response submitted by the Company. “We are pleased with the resolution of t

GlobeNewswire 7 months ago

VIGL
-2.11%
Vigil Neuroscience to Present at Cantor Global Healthcare Conference

WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 9:45 a.m. ET. To register for the live webcast, please click here. The webcast will also be available on the Company’s websi

GlobeNewswire 7 months ago

VIGL
-2.11%
Vigil Neuroscience to Present at Upcoming September Investor Conferences

WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at two upcoming investor conferences. Morgan Stanley 22nd Annual Global Healthcare ConferenceFormat: Fireside ChatDate/Time: Thursday, September 5th at 2:35 p.m. ET H.C. Wainwright 26th Annual Global Investment Confe

GlobeNewswire 8 months ago

VIGL
-2.11%

Performance Overview

Return	VIGL	S&P 500 (^GSPC)
YTD	+36.47%	+0.60%
1-Year	-33.43%	+11.47%
3-Year	+0.87%	+47.05%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vigil Neuroscience, Inc. (VIGL)

Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know

Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum

Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely?

Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

Vigil Neuroscience to Present at Upcoming Investor Conferences

Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stake

Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

Vigil Neuroscience to Present at Upcoming September Investor Conferences

Performance Overview